Tier 1 — highest

Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial

Bridie Thompson, Mary Waterhouse, Dallas R English, Donald S McLeod, Bruce K Armstrong, Catherine Baxter, Briony Duarte Romero, Peter R Ebeling, Gunter Hartel, Michael G Kimlin, Sabbir T Rahman, Jolieke C van der Pols, Alison J Venn, Penelope M Webb, David C Whiteman, Rachel E Neale
BMJ (Clinical research ed.) 2023 381:e075230

Bibliography

PubMed
PMID 37380191
PubMed Central
PMC10302209
DOI
10.1136/bmj-2023-075230
Funding
Support is recorded from Australian National Health and Medical Research Council. See the original publication for grant and material-support details.
Competing interests
The source discloses financial, employment, advisory or material-support relationships involving DSM. See the publication for the authors and nature of each relationship.

Study snapshot

DesignCardiovascular analysis of the randomized D-Health trial
ModelHuman participants
Sample21,302 participants included in this analysis
InterventionVitamin D3 60,000 IU monthly or placebo
DurationUp to 5 years
EndpointsMajor cardiovascular events; Myocardial infarction; Stroke; Coronary revascularization

What the study showed, in plain terms

This publication examines major cardiovascular events, myocardial infarction, stroke, coronary revascularization. Study population or evidence base: 21,302 participants included in this analysis. Intervention or exposure: Vitamin D3 60,000 IU monthly or placebo.

Key findings

The composite event estimate modestly favored vitamin D, but its confidence interval included no effect. Myocardial infarction showed a favorable secondary signal.

What this study can and cannot tell us

A secondary outcome analysis with small absolute differences and multiple comparisons. Monthly dosing should be distinguished from daily supplementation.

Related papers in the corpus

Tier 1
The effect of vitamin D supplementation on cancer incidence in the randomised controlled D-Health Trial: Implications for policy and practice
Rachel E Neale et al. · The Journal of steroid biochemistry and molecular biology · 2025
Tier 1
Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo-controlled D-Health Trial
Mary Waterhouse et al. · Journal of cachexia, sarcopenia and muscle · 2021
Tier 1
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality
Rachel E Neale et al. · The lancet. Diabetes & endocrinology · 2022
Tier 1
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
JoAnn E Manson et al. · The New England journal of medicine · 2019
Tier 1
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
Meryl S LeBoff et al. · The New England journal of medicine · 2022
Tier 1
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Jill Hahn et al. · BMJ (Clinical research ed.) · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research